Phase III results put obinutuzumab in line for approval ...

New findings from Spherix Global Insights’ Patient Chart Dynamix™: Lupus Nephritis (US), 2025 report reveal a treatment landscape in transition as specialists increasingly incorporate biologics, ...

Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a ...

March is National Kidney Month, a time to shine a light on the thousands of individuals whose lives are deeply affected by ...

Now the Vice President of Research at the Lupus Foundation of America, Dr. Buie’s work stems from that curiosity as well as ...

A “living drug” was developed as a cancer treatment. Now it is showing promise for conditions, such as lupus and multiple ...

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that its abstract detailing clinical results ongoing Phase 1/2 trial ...

For the millions of people living with lupus – a chronic autoimmune disease that can damage the kidneys, brain and other ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

InvestigateTV+ shares a young mother’s struggle with the debilitating effects of lupus. Plus, we take an in-depth look at ...

Shontia Matlock shares her experience managing lupus and rheumatoid arthritis. Discover how she navigates treatment, faces emotional challenges, and advocates for herself.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the Phase III ALLEGORY trial of Gazyva® (obinutuzumab) in adults with systemic lupus ...